Abstract
Background
Acute kidney injury (AKI) might complicate antihypertensive therapy. In The Netherlands, general practitioner clinical practice guidelines provide clear recommendations on monitoring of renal function to minimize this risk. Our objective was to investigate how day-to-day clinical practice corresponds to the guidelines.
Methods
We conducted a retrospective cohort study in a dynamic population, using data on >9,000 adults that was retrieved from the Integrated Primary Care Information database. We investigated whether serum creatinine (SCR) was measured within 30 and 365 days after the start of (combined) use of a diuretic, an angiotensin-converting enzyme inhibitor, and/or angiotensin receptor blocker. We also investigated the association between calendar year, sex, type of therapy, risk factors for AKI and practice and SCR measurement.
Results
Of 6,593 subjects who met the study criteria for single drug therapy, SCR was measured in 1,233 subjects within 30 days and in 3,896 subjects within 365 days. For combined drug therapy recipients (n = 2,497), these were 545 and 1,687, respectively. Associated cumulative probabilities were 19 % and 66 % with single drug therapy, and 22 % and 74 % with combined drug therapy. Significant differences were observed between practices. SCR measurement was associated with other characteristics, except for sex. Within 365 days, SCR increased >30 % of baseline in 103 subjects (1.6 %) after the start of single drug therapy, and in 85 (3.4 %) subjects who initiated combined drug therapy. In the majority (>70 %) of these subjects, this did not result in subsequent monitoring or adjustment of antihypertensive treatment.
Conclusions
Results from this study suggest that, on average, renal function is not monitored as strictly as recommended by relevant clinical practice guidelines.
Similar content being viewed by others
References
Jafar TH, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73–87.
Gelfand ML, Garren MG, Rowan RL. Acute anuria associated with chlorothiazide and hydrochlorothiazide therapy: recovery. N Y State J Med. 1964;64:1865–70.
Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.
Yusuf S, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.
Lapi F, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
The National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care; 2011. http://www.nice.org.uk/nicemedia/live/12069/42116/42116.pdf.
The Dutch College of General Practitioners. Cardiovascular risk management. 1st revision [Cardiovasculair risicomanagement (eerste herziening)]; 2012. https://www.nhg.org/standaarden/volledig/cardiovasculair-risicomanagement#Begrippen.
Kalra PA, et al. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318(7178):234–7.
Hurley JS, et al. Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med. 2005;20(4):331–3.
Raebel MA, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007;16(1):55–64.
Gerardin-Marais M, et al. Diuretic drug therapy monitoring in the elderly: a cohort study. Eur J Clin Pharmacol. 2008;64(4):433–7.
Coleman JJ, et al. Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care. Br J Clin Pharmacol. 2010;70(1):109–17.
Bootsma JE, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf. 2011;34(7):605–14.
Fournier JP, et al. Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study. PLoS ONE. 2012;7(3):e34187.
Geerts AF, et al. A pharmacy medication alert system based on renal function in older patients. Br J Gen Pract. 2012;62(601):e525–9.
Mathieson L, Severn A, Guthrie B. Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study. Scott Med J. 2013;58(2):69–76.
McDowell SE, et al. Laboratory monitoring and adverse patient outcomes with antihypertensive therapy in primary care. Pharmacoepidemiol Drug Saf. 2010;19(5):482–9.
Vlug AE, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 1999;38(4–5):339–44.
van der Lei J, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med. 1993;119(10):1036–41.
Hvidberg E, Andersen AH. New classification of drugs. The Medical list and the Drug catalogue are introduced in Anatomical–Therapeutic–Chemical classification code (ACT-code) in 1981. Ugeskr Laeger. 1980;142(6):396–7.
Knight EL, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138(5 Pt 1):849–55.
Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):19–62.
Thomas MC. Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Aust. 2000;172(4):184–5.
Verduijn M, Folmer H. Pharmacotherapeutic guideline pain management [Farmacotherapeutische richtlijn pijnbestrijding]; 2007. http://download.nhg.org/FTP_NHG/standaarden/FTR/Pijnbestrijding_text.html#noot18.
Platts-Mills TF, et al. Life-threatening hyperkalemia after 2 days of ibuprofen. Am J Emerg Med. 2013;31(2):465 e1–2.
Hsu CY, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72(2):208–12.
Onuigbo MA. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin Pract. 2011;118(4):c407–19.
Fried LF, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–903.
Makani H, et al. Efficacy and safety of dual blockade of the renin–angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.
McDowell SE, Ferner RE. Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review. Drug Saf. 2011;34:1049–59.
Bardach NS, et al. Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310(10):1051–9.
Scott A, et al. The effect of financial incentives on the quality of health care provided by primary care physicians. Cochrane Database Syst Rev. 2011;9:CD008451.
Roksnoer LC, et al. Urinary markers of intrarenal renin–angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15(2):81–8.
Wong J. Is there benefit in dual renin–angiotensin–aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diab Vasc Dis Res. 2013;10(3):193–201.
Acknowledgments
We thank Marcel de Wilde, Kris Sieradzan and Mees Mosseveld for the collection of data and maintenance of the IPCI database.
Conflicts of interest
No sources of funding were used to assist in the preparation of this study. Miriam C. Sturkenboom is heading a research group that occasionally conducts research for pharmaceutical companies, including Novartis, Boehringer Ingelheim, Pfizer and Eli Lilly. None of these are related to the subject of this manuscript. Katia M. Verhamme has received unconditional grants from Yamanouchi, Boehringer Ingelheim, Pfizer and Novartis. None of these are related to the subject of this manuscript. Jan C. van Blijderveen, Sabine M. Straus, Maria A. de Ridder and Bruno H. Stricker have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Blijderveen, J.C., Straus, S.M., de Ridder, M.A. et al. Adherence to Renal Function Monitoring Guidelines in Patients Starting Antihypertensive Therapy with Diuretics and RAAS Inhibitors: A Retrospective Cohort Study. Drug Saf 37, 369–377 (2014). https://doi.org/10.1007/s40264-014-0160-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-014-0160-0